首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MCP1 |
| Uniprot No | P13500 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-99aa |
| 氨基酸序列 | QPDAINAPVT CCYNFTNRKI SVQRLASYRR ITSSKCPKEA VIFKTIVAKE ICADPKQKWV QDSMDHLDKQ TQTPKT |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MCP1(单核细胞趋化蛋白1.CCL2)重组蛋白的3篇代表性文献摘要概括：
1. **文献名称**：*"Molecular cloning and functional expression of human monocyte chemoattractant protein 1 (MCP1)"*
**作者**：Yoshimura, T. 等
**摘要**：该研究首次克隆了人类MCP1的基因，并通过重组表达系统在哺乳动物细胞中成功表达功能性MCP1蛋白。实验验证了其趋化单核细胞的能力，并确认其与CCR2受体的特异性结合。
2. **文献名称**：*"Role of MCP1 in atherosclerosis and tumor angiogenesis"*
**作者**：Rollins, B.J. 等
**摘要**：通过重组MCP1蛋白的体外和动物实验，发现MCP1在动脉粥样硬化斑块形成中促进单核细胞浸润，同时在肿瘤微环境中增强血管生成，提示其作为炎症和癌症治疗的潜在靶点。
3. **文献名称**：*"Neutralization of MCP1 by recombinant antibodies inhibits neuropathic pain in murine models"*
**作者**：Bhangoo, S. 等
**摘要**：研究利用重组MCP1蛋白免疫动物制备中和抗体，证明阻断MCP1可显著减少神经损伤模型中的小胶质细胞活化和疼痛行为，为慢性疼痛治疗提供新策略。
4. **文献名称**：*"Crystal structure of recombinant human MCP1 reveals structural basis for receptor binding"*
**作者**：Handel, T.M. 等
**摘要**：通过X射线晶体学解析重组人MCP1的三维结构，揭示了其与受体CCR2结合的关键结构域，为设计靶向MCP1的小分子抑制剂奠定基础。
以上文献涵盖MCP1重组蛋白的分子机制、疾病关联及治疗应用，建议结合具体研究方向进一步筛选。
**Background of MCP1 Recombinant Protein**
Monocyte chemoattractant protein-1 (MCP1), also known as CCL2 (C-C motif chemokine ligand 2), is a small cytokine belonging to the CC chemokine family. It plays a critical role in recruiting immune cells, particularly monocytes, memory T cells, and dendritic cells, to sites of inflammation, infection, or injury. MCP1 binds to its cognate receptor, CCR2. triggering intracellular signaling pathways that mediate cell migration and activation. Dysregulated MCP1 expression is implicated in various pathological conditions, including atherosclerosis, rheumatoid arthritis, neuroinflammation, and cancer metastasis, making it a key target for therapeutic research.
Recombinant MCP1 protein is produced using genetic engineering techniques, often in *E. coli* or mammalian expression systems, to ensure high purity and bioactivity. The recombinant form retains the functional properties of native MCP1. enabling its use in *in vitro* and *in vivo* studies to investigate immune responses, disease mechanisms, and potential therapies. For instance, it is employed in chemotaxis assays to study leukocyte migration, in inflammation models to assess drug efficacy, or as a reference standard in biomarker quantification.
Additionally, MCP1 recombinant protein serves as a tool for developing neutralizing antibodies or inhibitors targeting the MCP1/CCR2 axis, which is explored in clinical trials for conditions like diabetic nephropathy and chronic pain. Its role in tumor-associated macrophage infiltration has also spurred interest in cancer immunotherapy.
Overall, MCP1 recombinant protein is a vital reagent in biomedical research, bridging mechanistic studies and therapeutic development in inflammation-related diseases.
×
